Voici une nouvelle étude qui montre l’efficacité de l’homéopathie selon les critères en vigueur de l’ancienne école.
En réitérant toutes mes réserves sur ce genre d’approche, vous remarquerez que l’homéopathie même scientifiquement massacrée semble donner des résultats. Donner à la même dynamisation, 4c, le même épouvantable mélange de Arnica, Lachesis, Sanguinaria, et Glonoin ne représente qu’une caricature de l’homéopathie.
Pourquoi une 4c? La réponse tient dans la faible homéopathicité du mélange administré. Plus la « résolution » est basse, plus il y a de chances que l’organisme accepte de répondre au stimulus. En donnant à une si basse dynamisation on se base quasiment sur un effet toxicologique des médicaments administrés. Le temps de l’étude, les cobaye qui prennent ces poisons verront probablement une diminution de leurs bouffées, qui reviendront avec d’autant plus de violence une fois stoppé le drogage.
Bref, une atrocité de plus qui ne prouve rien, ni en faveur de l’homéopathie, ni en faveur de la compétence des auteurs.

bouffes de chaleurEfficacy of a Non-Hormonal Treatment, BRN-01, on Menopausal Hot Flashes: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Auteurs: Colau, Jean-Claude; Vincent, Stéphane; Marijnen, Philippe; Allaert, François-André

Abstract

Background: Homeopathic medicines have a place among the non-hormonal therapies for the treatment of hot flashes during the menopause.

Objective: The objective of this study was to evaluate the efficacy of the non-hormonal treatment BRN-01 in reducing hot flashes in menopausal women.

Study Design: This was a multicenter, randomized, double-blind, placebo-controlled study carried out between June 2010 and July 2011.

Setting: The study was conducted in 35 active centers in France (gynecologists in private practice).

Patients: One hundred and eight menopausal women, ]=50 years of age, were enrolled in the study. The eligibility criteria included menopause for =5 hot flashes per day with a significant negative effect on the women’s professional and/or personal life.

Intervention: Treatment was either BRN-01 tablets, a registered homeopathic medicine containing Actaea racemosa (4 centesimal dilutions [4CH]), Arnica montana (4CH), Glonoinum (4CH), Lachesis mutus (5CH), and Sanguinaria canadensis (4CH), or identical placebo tablets, prepared by Laboratoires Boiron according to European Pharmacopoeia standards. Oral treatment (2 to 4 tablets per day) was started on day 3 after study enrollment and was continued for 12 weeks.

Main Outcome Measure: The main outcome measure was the hot flash score (HFS) compared before, during, and after treatment. Secondary outcome criteria were the quality of life (QoL) [measured using the Hot Flash Related Daily Interference Scale (HFRDIS)], severity of symptoms (measured using the Menopause Rating Scale), evolution of the mean dosage, and compliance. All adverse events (AEs) were recorded.

Results: One hundred and one women were included in the final analysis (intent-to-treat population: BRN-01, n=50; placebo, n=51). The global HFS over the 12 weeks, assessed as the area under the curve (AUC) adjusted for baseline values, was significantly lower in the BRN-01 group than in the placebo group (mean +/- SD 88.2 +/- 6.5 versus 107.2 +/- 6.4; p=0.0411). BRN-01 was well tolerated; the frequency of AEs was similar in the two treatment groups, and no serious AEs were attributable to BRN-01.

Conclusion: BRN-01 seemed to have a significant effect on the HFS, compared with placebo. According to the results of this clinical trial, BRN-01 may be considered a new therapeutic option with a safe profile for hot flashes in menopausal women who do not want or are not able to take hormone replacement therapy or other recognized treatments for this indication.

Trial registration number (EudraCT): 2009-016959-21.

Copyright 2012 Adis Data Information BV

Tags: , , ,

Pas encore de commentaire.

Laisser un commentaire

Vous devez être connecté pour poster un commentaire.